Literature DB >> 24516728

Dissemination of ST274 Klebsiella pneumoniae epidemic clone in newborn and adult hospital settings harbouring SHV-2A or CTX-M-15 type extended spectrum β-lactamases-producing known plasmids.

I Damjanova, A Tóth, E Kenesei, M Köhalmi, P Szántai, M Füzi, J Pászti.   

Abstract

Molecular epidemiology and genetic features of an extended-spectrum β-lactamase (ESBL) producing Klebsiella pneumoniae epidemic clone (KP-EC) with elevated ciprofloxacin MIC (minimum inhibitory concentration) values from multiple nosocomial outbreaks and sporadic cases between 2006 and 2008 in Hungary were investigated. As a result of continuous monitoring of ESBL-producing KP-ECs, 27 isolates collected from five healthcare facilities were selected for macrorestriction profile analysis by PFGE (pulsed field gel electrophoresis). Of these, 12 strains were isolated from adult inpatients, while 15 strains were from newborns. The MIC values for several antibiotics were determined by agar dilution technique. Molecular typing was further performed by PCR (polymerase chain reaction) and sequencing of several antibiotic resistance genes, plasmid profile analysis, transfer of resistance determinants and multilocus sequence typing (MLST). All isolates showed moderate resistance to ciprofloxacin (MICs ranged from 0.5 to 8 mg L(-1)). PFGE revealed the existence of only one genetic cluster defined as EC IV. PstI digestion of plasmid DNA revealed two highly diverse restriction patterns in "adult" and "newborn" isolates corresponding to plasmids from the Hungarian Epidemic Clone and plasmids isolated from a neonatal nosocomial outbreak in 1998, respectively. Sequence analysis of β-lactamase genes from plasmids of 14 selected isolates detected bla SHV-2a in strains isolated exclusively from newborns and bla CTX-M-15 in strains isolated exclusively from adult inpatients. MLST established that strains of the PFGE cluster belonged to a novel sequence type ST274. ESBL-producing K. pneumoniae isolates belonging to the novel sequence type ST274 appeared in the newborn and adult hospital settings in Hungary and acquired SHV-2a or CTX-M-15 type enzymes, respectively. Thus, a new antimicrobial resistance strategy for successful conformation to distinct hospital settings was found.

Entities:  

Keywords:  Klebsiella pneumoniae; MLST; allodemic plasmid; clonal spread

Year:  2011        PMID: 24516728      PMCID: PMC3906618          DOI: 10.1556/EuJMI.1.2011.3.6

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  16 in total

1.  Occurrence and regional distribution of SHV-type extended-spectrum beta-lactamases in Hungary.

Authors:  A Tóth; M Gacs; K Márialigeti; G Cech; M Füzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

2.  Identification of the plasmid-borne quinolone resistance gene qnrS in Salmonella enterica serovar Infantis.

Authors:  Corinna Kehrenberg; Sonja Friederichs; Anno de Jong; Geovana Brenner Michael; Stefan Schwarz
Journal:  J Antimicrob Chemother       Date:  2006-05-23       Impact factor: 5.790

3.  Epidemiology of SHV-type beta-lactamase-producing Klebsiella spp. from outbreaks in five geographically distant Hungarian neonatal intensive care units: widespread dissemination of epidemic R-plasmids.

Authors:  Ivelina Damjanova; Akos Tóth; Judit Pászti; Melinda Jakab; Hedda Milch; Adolf Bauernfeind; Miklós Füzi
Journal:  Int J Antimicrob Agents       Date:  2007-03-21       Impact factor: 5.283

4.  Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?

Authors:  Ivelina Damjanova; Akos Tóth; Judit Pászti; Gabriella Hajbel-Vékony; Melinda Jakab; Judit Berta; Hedda Milch; Miklós Füzi
Journal:  J Antimicrob Chemother       Date:  2008-07-30       Impact factor: 5.790

5.  Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.

Authors:  Ari Robicsek; Jacob Strahilevitz; George A Jacoby; Mark Macielag; Darren Abbanat; Chi Hye Park; Karen Bush; David C Hooper
Journal:  Nat Med       Date:  2005-12-20       Impact factor: 53.440

6.  Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom.

Authors:  E Karisik; M J Ellington; R Pike; R E Warren; D M Livermore; N Woodford
Journal:  J Antimicrob Chemother       Date:  2006-07-26       Impact factor: 5.790

Review 7.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

8.  Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli.

Authors:  Anja Schumacher; Petra Steinke; Jürgen A Bohnert; Murat Akova; Daniel Jonas; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2005-12-14       Impact factor: 5.790

Review 9.  The worldwide emergence of plasmid-mediated quinolone resistance.

Authors:  Ari Robicsek; George A Jacoby; David C Hooper
Journal:  Lancet Infect Dis       Date:  2006-10       Impact factor: 25.071

10.  Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae.

Authors:  F M E Wagenlehner; P Heisig; C Irtenkauf; F Notka; J Decker; N Lehn; H Linde
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  1 in total

1.  The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis.

Authors:  Wu-Pu Lin; Jann-Tay Wang; Shan-Chwen Chang; Feng-Yee Chang; Chang-Phone Fung; Yin-Ching Chuang; Yao-Shen Chen; Yih-Ru Shiau; Mei-Chen Tan; Hui-Ying Wang; Jui-Fen Lai; I-Wen Huang; Tsai-Ling Lauderdale
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.